During the next few months, while the two companies are establishing the sales strategy for Germany, CellaVision's product DiffMaster will be under evaluation by potential German customers.
"We estimate the German market to be 3-4 times larger than the Scandinavian market," says Yvonne Mårtensson, CEO of CellaVision, "so collaboration with a well-established local partner is therefore highly valuable. It's also an important first step into the global market."
CellaVision and Sysmex are also discussing strategic collaboration in the fields of digital image processing and hematology analysis.
- Last November, Sysmex signed a Letter of Intent regarding distribution of CellaVision's products in selected countries, starting with Germany.
- CellaVision recently received FDA approval (from the Food and Drug Administration in the USA) to sell DiffMaster(TM) Octavia in the USA.
- CellaVision has sold its first DiffMaster(TM). Malmö General Hospital (MAS), the university hospital in the southern Swedish town of Malmö, has decided to install CellaVision's system for digital image processing of blood cells at its clinical chemical laboratory. The laboratory will become a strategic partner to CellaVision for further development of the system.